Monoclonal Antibody to Leucine Rich Alpha-2-Glycoprotein 1 (LRG1)
| Code | Size | Price |
|---|
| MAB934Ra22-20ul | 20ul | £92.00 |
Quantity:
| MAB934Ra22-100ul | 100ul | £173.00 |
Quantity:
| MAB934Ra22-200ul | 200ul | £235.00 |
Quantity:
| MAB934Ra22-1ml | 1ml | £542.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Immunocytochemistry (ICC)
- Immunofluorescence (IF)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Leucine Rich Alpha-2-Glycoprotein 1
Potency (Clone Number):
1:810000 (C1)
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-5ug/ml<br/>Immunocytochemistry in formalin fixed cells: 5-30ug/ml<br/>Immunohistochemistry in formalin fixed frozen section: 5-30ug/ml<br/>Immunohistochemistry in paraffin section: 5-30ug/ml<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) | RPB934Ra02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||